ArticleFrontiers in cellular and infection microbiology2025
Biotherapeutic potential of different fractions of cell-free supernatants from
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Beyond probiotics: Lacticaseibacillus rhamnosus as a multi-target antagonist of Pseudomonas aeruginosa infections.Folia microbiologica · 2026Review
- Review
- Postbiotics as Multifunctional Bioactives: Mechanistic Insights and Translational Applications in Host Physiology and Microbial Ecosystem Modulation.Microorganisms · 2026Review
- Cell-Free but potent: Antimicrobial potential of Lactobacillus supernatants against multidrug-resistant pathogens.PloS one · 2026Article
- Article
- Proteomic Analysis of the Differential Response ofAntibiotics (Basel, Switzerland) · 2025Article
- Activity in an air-liquid interface lung infection model, feasibility of inhaled delivery, and stability of cell-free supernatants fromFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Due to their content of multiple antimicrobial bioactive substances, cell-free supernatants (CFS) from lactic acid bacteria are emerging as novel antimicrobials. We have previously demonstrated that CFS from Methods: A Results: Both antibacterial and antibiofilm activities were mainly, but not exclusively, ascribed to the low molecular weight CFS fraction (≤ 3 kDa), which contained most of the lactic acid, suggesting a major role of this component in the antimicrobial effect of CFS. The > 3 kDa fraction alone was almost inactive but displayed a synergistic antibacterial effect when reconstituted with the ≤ 3 kDa fraction. Proteomics analysis of CFS revealed the presence of cell wall hydrolases, suggesting that these enzymes might contribute to the antibacterial activity observed in the reconstituted fractions. Following 6 h stimulation of PBMC with LPS or biofilm-derived Conclusion: The obtained results support that, due to their multiple antimicrobial and anti-inflammatory effects, probiotic metabolites might represent a promising strategy for the prevention and/or treatment of chronic infections with an intense inflammatory response such as those caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.